Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
The phase 2b Parkinson’s trial missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
Nick Paul Taylor
May 22, 2026 6:12am
Herantis taps Indivi for digital biomarker tech in new trial
May 19, 2026 7:45am
Novo salvages happy ending for scrapped Parkinson’s therapy
May 11, 2026 8:30am
Oryon shines out of stealth with $21M to fight Parkinson's
Mar 23, 2026 5:00am
Aspen's Parkinson's cell therapy data plant seeds for ph. 3
Mar 18, 2026 9:00am
Biohaven reduces scope of R&D cuts as pipeline progresses
Mar 3, 2026 9:00am
